Citalopram and Alcohol: Why This One Is About the Heart

Most pages about antidepressants and alcohol are about sedation. Citalopram is the SSRI where that is the least interesting part of the answer, and where its own licensed label says so.

What makes citalopram different is a documented, dose-dependent effect on the QT interval, a measure of how long the heart takes to reset between beats. UK regulators acted on it. Heavy drinking pushes the same measurement in the same direction, by a route the regulators did not write about. Putting those two facts next to each other is what this page is for. It does not tell you how much you can drink, because nobody can answer that from a web page.

If you are having thoughts of harming yourself, contact emergency services where you are. In the UK that is 999, or NHS 111 for urgent advice.

What the UK sources actually say

Four sources address this directly, and one of them contradicts itself in a single paragraph.

The Summary of Product Characteristics is the regulated document behind the medicine, and its alcohol entry is two sentences long. The first says nothing has been demonstrated. The second advises against the combination anyway. The patient leaflet performs the same manoeuvre in one breath.

Our reading is that this is a regulator declining to certify a combination it has no positive reason to endorse. It is worth noticing, because it means the case against drinking on citalopram does not rest on a proven chemical interaction. It rests on something else.

The part that is specific to citalopram

Citalopram carries a cardiac warning that most SSRIs do not.

The label states that “Citalopram has been found to cause a dose-dependent prolongation of the QT-interval”, and that cases of QT prolongation and ventricular arrhythmia including torsade de pointes have been reported after marketing, “predominantly in patients of female gender, with hypokalaemia, or with pre-existing QT prolongation or other cardiac diseases”. Torsade de pointes is the abnormal rhythm the NHS page is describing when it lists, among citalopram’s serious side effects, “a rare, life-threatening condition that causes a fast, irregular heartbeat, light-headedness and fainting”.

In 2011 the MHRA acted on this after a Europe-wide review. It restricted the maximum daily dose of citalopram, restricted it further again in people over 65 and in people with liver impairment, and said patients already above the new ceiling should have their treatment reviewed. We are deliberately not printing those figures here, because a number on a web page next to the word “maximum” gets read as personal permission. Your prescriber has them.

Three parts of that regulatory advice matter more to this page than the numbers do:

• Citalopram is contraindicated in people with congenital long QT syndrome or known pre-existing QT prolongation, and in combination with other medicines known to prolong the QT interval.
• “Electrolyte disturbances (eg, hypokalaemia and hypomagnesaemia) should be corrected before treatment.”
• Caution is advised in significant bradycardia, recent heart attack, or decompensated heart failure.

That middle bullet is the hinge of this page. Low potassium and low magnesium are the two blood results the regulator wants corrected before treatment starts. They are also two of the more predictable consequences of sustained heavy drinking.

Where alcohol meets the QT question

Three separate lines of evidence connect drinking to the same measurement. They are not equally strong, and it matters which is which.

The electrolyte route is the strongest. Moulin and colleagues compared 62 people who were actively drinking with 104 who had been abstinent. Prolonged QT was found in 16 per cent of the active group against 2 per cent of the abstinent group, and low magnesium in 23 per cent against 10 per cent. Magnesium ran inversely to QT length in the active drinkers. The awkward part, published here because it is real, is that the same authors found no significant difference in serum electrolytes between participants who did and did not have a long QT. The association is there. This study does not cleanly prove the mechanism.

The direct route is the weakest. The largest general-population study we found, Zhang and colleagues in 7,795 American adults, found that drinking seven or more drinks a week made almost no difference to QT duration once other factors were accounted for. Only binge drinking, and only in men, showed a measurable effect, of a few milliseconds. The authors were candid that the clinical significance of a change that small is uncertain. A separate study of 11,269 adults by Li and colleagues found heavy drinkers, but not moderate drinkers, had higher odds of a prolonged QTc. Our reading of the two together is that ordinary drinking is not doing much to your QT interval, and heavy drinking is.

The withdrawal route is the one people do not expect. Otero-Antón and colleagues measured ECGs in 62 patients admitted with alcohol withdrawal syndrome and found a prolonged QTc in 46.8 per cent of them on admission. In everyone who had a repeat ECG after recovering, it returned to normal. So the riskiest cardiac moment for a heavy drinker on citalopram may not be the drinking. It may be the unplanned stop.

Now the inconvenient half, and it is substantial. The MHRA safety update does not mention alcohol at any point. The citalopram label does not list alcohol among the QT risk factors it names. Nobody has run the study that would settle this. Joining these findings to citalopram’s own QT signal is our synthesis, not a conclusion any of these sources drew. Read it as a reason to tell your prescriber how much you drink, not as a risk anyone can put a number on.

The sedation question, briefly

Citalopram is genuinely unusual here, and it cuts in the reassuring direction.

Its label states that in humans citalopram “does not impair cognitive (intellectual function) and psychomotor performance and has no or minimal sedative properties, either alone or in combination with alcohol”. A licensed label saying that much about the combination is unusual, and it is why this page has not been written around drowsiness.

Two caveats keep it honest. The label still rates citalopram as having a minor or moderate influence on driving, warns that psychoactive medicines can reduce the ability to judge and react to emergencies, and notes the illness itself impairs attention. And in overdose, the label says plainly that “the effects will be potentiated by alcohol taken at the same time”.

Escitalopram is the same question

Escitalopram is the S enantiomer of citalopram, one half of the same molecule sold on its own. The MHRA safety update covers both in a single document, applied the same kind of dose restriction to each, and its alcohol wording is near-identical. The escitalopram label says: “No pharmacodynamic or pharmacokinetic interactions are expected between escitalopram and alcohol. However, as with other psychotropic medicinal products, the combination with alcohol is not advisable.”

Where the two part company is on the NHS website. The citalopram page warns generally about side effects; the escitalopram page specifies “making you feel more sleepy”. The licensed label describes minimal sedative properties in combination with alcohol, but citalopram does have mild sedative effects, so a sleepiness warning is clinically reasonable.

If you are drinking because you are depressed

Our observation is that a page like this reaches this group more often than it reaches anyone with a cardiac history, and they deserve better than a warning.

Start with what national guidance does not say. NICE NG222, the current guideline on treating depression in adults, contains no recommendation about drinking while taking an antidepressant. Alcohol appears in its recommendations only in passing: as something to ask about at assessment, as part of the instructions people should be given for taking their medication, and in general advice about not over-using it. Silence is not permission. It means the question was not the guideline’s job.

The guidance that does address it directly is NICE CG115 on alcohol-use disorders, and it says something people find counter-intuitive: “For people who misuse alcohol and have comorbid depression or anxiety disorders, treat the alcohol misuse first as this may lead to significant improvement in the depression and anxiety.” It goes on to say that if the depression or anxiety continues after a period of abstinence from alcohol, it should be assessed, with referral and treatment considered in line with the relevant NICE guideline for that disorder.

Read that carefully. It is written for clinicians deciding what to treat first. It is not an instruction to anyone already taking citalopram to stop it. NICE separately asks people who want to stop an antidepressant to talk to whoever prescribed it, and explains that the dose usually has to come down in stages. Nothing here is permission to stop, and skipping doses to clear an evening is the worst version of both choices.

If the honest answer to “how much do you drink” is one you would rather not give, that is the sentence worth taking to the appointment. On citalopram it changes what a prescriber weighs, because it touches electrolytes, liver function and cardiac risk factors at once.

And do not stop drinking suddenly on your own either

If you have been drinking heavily every day, stopping abruptly without support can be dangerous. That is true for anyone. The withdrawal ECG finding above is why it is worth repeating on a citalopram page in particular: the period after an unplanned stop is when QT prolongation was most commonly recorded in that group, and it is the period when someone is least likely to be under observation.

Assisted withdrawal exists so that this does not have to be survived alone. Our pages on medications used in alcohol withdrawal and whether detox at home is realistic set out what that involves.

Talking to us, if it has got to that point

The Orchid Recovery is a residential addiction and mental health treatment centre in Hang Dong District, Chiang Mai, Thailand, for international English speaking adults. Where depression and drinking are holding each other up, both need treating, which is what dual diagnosis means in practice. Our pages on medically supervised alcohol detox, alcohol addiction treatment and depression treatment explain what we do, our clinical team is listed here, and you can talk to us.

We do not change anyone’s antidepressant remotely, and would not do so on the basis of a web page. Most people who read this need their own prescriber, not us, and that is the right outcome. We have written separately about pregabalin and alcohol, where the interaction is a direct one rather than a shared risk factor.

Sources

• NHS, Citalopram
• NHS, Escitalopram
• electronic Medicines Compendium, Citalopram 20mg Tablets, Summary of Product Characteristics
• electronic Medicines Compendium, Citalopram 20mg Tablets, Patient Information Leaflet
• electronic Medicines Compendium, Escitalopram 10 mg film-coated tablets, Summary of Product Characteristics
• MHRA Drug Safety Update, Citalopram and escitalopram: QT interval prolongation
• NICE, Depression in adults: treatment and management (NG222)
• NICE, Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence (CG115)
• Moulin SR et al, QT interval prolongation associated with low magnesium in chronic alcoholics, Drug and Alcohol Dependence 2015;155:195-201
• Li Z et al, Relation of Heavy Alcohol Consumption to QTc Interval Prolongation, American Journal of Cardiology 2016;118:1201-1206
• Otero-Antón E et al, Prolongation of the QTc interval during alcohol withdrawal syndrome, Acta Cardiologica 1997;52:285-294
• Zhang Y et al, Coffee, Alcohol, Smoking, Physical Activity and QT Interval Duration, PLoS ONE 2011;6(2):e17584
• Mahendran M et al, Binge alcohol consumption leading to hypokalemic rhabdomyolysis, BMJ Case Reports 2019
• Newell et al, Sedation mediates part of citalopram’s effect on agitation in Alzheimer’s disease, Journal of Psychiatric Research 2016

When the drinking is the part that will not move

Nothing here is a reason to touch your prescription. That decision belongs to the person who wrote it, and this section does not change that in either direction.

What it is for is the reader who has worked out, somewhere in the last few paragraphs, that cutting down is not currently something they can do. Depression and heavy drinking hold each other up, and treating one while the other continues tends not to hold. Our residential programme in Chiang Mai is built for that overlap, with a full-time psychiatrist on site, assisted withdrawal where the assessment calls for it, and depression treatment running alongside rather than afterwards. Fees start at USD $10,900 and are published, which is only worth mentioning because comparing options is otherwise unnecessarily hard.

To talk it through, +66 985 245 093 takes calls and WhatsApp. Use admissions@orchidrecoverythailand.com if a call from where you are is impractical, or if you are a partner or a parent asking on someone else’s behalf and would rather not be overheard.